Current treatments fail to provide adequate tumor suppression or clinical outcomes. Improving potency through synergistic bioactive compounds overcomes existing resistance and limited drug bioavailability.

Rapid enzymatic degradation and poor bioavailability of linear pyrazolopyrimidine derivatives. Macrocyclization addresses these failure modes to ensure sustained therapeutic concentrations.

Insufficient blood flow to neural and vascular tissues limits cognitive and cardiovascular recovery. Restoring perfusion improves clinical outcomes in cerebrovascular disorders.

Lipophilic phytochemicals and traditional formulations suffer from low solubility and metabolic instability. Overcoming these barriers ensures therapeutic concentrations reach target tissues.

Vascular obstructions and arterial plaque buildup lead to life-threatening cardiovascular events. Mitigating these biological blockages reduces mortality and improves systemic blood flow.